A Phase 1 clinical trial of KIF18A.
Latest Information Update: 28 Oct 2024
Price :
$35 *
At a glance
- Drugs Antineoplastics
- Indications Ovarian cancer; Triple negative breast cancer
- Focus Adverse reactions
- 28 Oct 2024 New trial record
- 24 Oct 2024 According to Accent Therapeutics Media, company anticipated to begin a Phase 1 trial in early 2025.